Cellix Bio Private Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Apr 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 16, 2026
- 1 fee due Aug 20, 2027The maintenance fee for Composition comprising lidocaine, l-carnosine and dexpanthenol (US 11,903,992) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,952,068 | Compositions for the Treatment of Diabetes and Pre-Diabetes In force · High confidence | In force | High confidence | |
| US 10,208,014 | Compositions and Methods for the Treatment of Neurological Disorders In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 10,227,301 | Compositions and Methods for the Treatment of Inflammation and Pain In force · Medium confidence | In force | Medium confidence | |
| US 11,465,973 | Compositions and methods for the treatment of oral infectious diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,649,215 | Compositions and methods for the treatment of oral infectious diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 11,643,419 | Compositions and methods for the treatment of xerostomia In force · From the USPTO record | In force | From the USPTO record | |
| US 11,485,730 | Compositions and methods for the treatment of fungal infections In force · From the USPTO record | In force | From the USPTO record | |
| US 11,555,007 | Compositions and Methods for the Treatment of Neurological Diseases In force · High confidence | In force | High confidence | |
| US 11,648,240 | Pharmaceutical composition comprising famotidine, lidocaine and melatonin In force · From the USPTO record | In force | From the USPTO record | |
| US 11,903,992 | Composition comprising lidocaine, l-carnosine and dexpanthenol In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 61 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 24 no status recorded